Thermo Fisher Scientific to Showcase Global Innovation at DCAT Week 2022

Thermo Fisher Scientific will highlight its recent investments and innovation across its global pharma services network from development to commercial at DCAT Week in New york City.

 

This year, Thermo Fisher will open one of the largest viral vector sites in North America. The nearly 300,000-square-foot facility in Plainville, MA, will extend the company’s global commercial viral vector network to six sites. 

 

Later this year, Thermo Fisher will expand its cell therapy network with the addition of a new cell therapy development and cGMP manufacturing center at the University of California San Francisco, Mission Bay campus. 

 

To address the need for commercial-quality plasmid DNA, Thermo Fisher opened its new cGMP Plasmid manufacturing facility in Carlsbad, CA, to support clinical and commercial needs for high quality raw material and drug substance development for cell and gene therapies and vaccines.

 

Additionally, the company is launching new mRNA synthesis capabilities to produce drug substance for vaccines and therapies.

 

Thermo Fisher has added new capabilities to support early-stage development, shorten pre-clinical study timelines and accelerate commercialization. New translational sciences labs will open in San Diego, CA, and Alachua, FL, to support cell and gene therapy development for the pharmaceutical innovators transitioning drug candidates into pre-clinical studies.

 

In addition, new Quick to Clinic integrated services connect services across the value chain and create workflows to allow rapid process development and reduced cycle times. New Quick to Care for advanced therapies offers an end-to-end, customizable solution that integrates drug development and clinical services across the cell and gene therapy value chain to speed access to breakthrough therapies. New Patheon Commercial Packaging Services for Cell and Gene Therapies combine GMP storage, serialization, ultracold and cryogenic packaging, and global distribution to meet specialized needs to ensure CGT supply chain integrity.

 

Steriles, Product Development & Biologics Capabilities

The company has expanded its capabilities to support the accelerated demand for global steriles and biologics manufacturing. Over the last two years, Thermo Fisher has added 13 new aseptic filling lines and expanded its product development services across its global network.

 

Thermo Fisher is doubling biologics manufacturing capacity at its St. Louis, MO, site to support production growth from 2KL to 5KL. In addition, the company assumed operational responsibility of its new state-of-the-art biologics manufacturing facility in Lengnau, Switzerland, which features highly flexible bioproduction technologies and provides a pathway from development to large-scale production.

 

Later this year, the company will expand into Asia-Pacific. In Hangzhou, China, a new manufacturing facility will be the first to offer integrated biologics drug substance and sterile drug product capabilities. In Singapore, a new sterile manufacturing facility will offer large-scale capacity and high-speed filling.

Thermo Fisher is leveraging new digital technologies across its pharma services network to create manufacturing efficiencies and streamlined processes.  New capabilities include implementation of Pharma 4.0 to harmonize and integrate data and drive digital transformation within all phases of drug development and manufacturing. In addition, the company’s new mysupply digital supply chain platform provides customers with visibility and collaboration across their full product lifecycle including daily order management, batch tracking and monthly forecasting.